v3.26.1
Segment Reporting (Tables)
 12 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of segment reporting information
        
   Year ended   Year ended 
   June 30, 2026   June 30, 2025 
         
Clinical studies  $8,177,000   $3,660,000 
Clinical teams   5,150,000    4,479,000 
Chemistry, manufacturing and controls   188,000    834,000 
Other research and development expenses   447,000    294,000 
General and administrative expenses   8,511,000    8,570,000 
Amortization of intangible assets   178,000    229,000 
Other income, net   (579,000)   (524,000)
Net loss  $(22,072,000)  $(17,542,000)